▶ MATRIXYL-3000 · SUBTOPIC · SAFETY PROFILE
MATRIXYL-3000 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of MATRIXYL-3000.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of MATRIXYL-3000. Severity, frequency, and attribution depend on the source publication.
- Topical · rare mild irritation
- No systemic absorption documented
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for MATRIXYL-3000.
- No documented topical-systemic drug interactions
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for MATRIXYL-3000 in the published record:
- Hypersensitivity to peptide ingredients
FDA REGULATORY STATUS
Cosmetic ingredient · not a drug. No FDA pharmaceutical approval required for topical cosmetic use.
WADA REGULATORY STATUS
Not listed on the WADA Prohibited List (cosmetic ingredient, no systemic exposure).
SAFETY Q+A FROM LITERATURE
▶ Is Matrixyl-3000 FDA-approved?
Matrixyl-3000 is a cosmetic ingredient, not a drug. The FDA does not pre-approve cosmetic ingredients in the same way as drugs. Topical cosmetic use is widespread under existing FDA cosmetic-ingredient regulations.
▶ Is Matrixyl-3000 safe?
Topical Matrixyl-3000 has no documented systemic absorption at cosmetic concentrations. The peptides are too large for significant transdermal absorption into the bloodstream. Rare mild local irritation is reported; no systemic side effects are described.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci 2000. link
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25